智通财经APP讯，白云山(00874)发布公告，近日，公司子公司广州白云山奇星药业有限公司(简称“奇星药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意奇星药业委托广州白云山医药集团股份有限公司白云山制药总(简称“白云山制药总厂”)厂生产虚汗停颗粒(无糖型)在原委托生产地址基础上，新增受托生产地址。
本次奇星药业委托白云山制药总厂生产虚汗停颗粒(无糖型)在原委托生产地址基础上，新增受托生产地址，有利于其增加产能，提高生产效率，满足市场需求。本次获得《药品生产许可证》，对本公司当期业绩无重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.